Shots:

• The companies collaborated to evaluate Carisma’s CAR-M + Merck’s Keytruda for HER2 overexpressing cancers patients. The study is expected to launch in 2022
• Carisma's CAR-M platform can reprogram the solid tumor microenvironment for immune activation, T cell recruitment & anti-tumor adaptive immunity, based on pre-clinical results
• In preliminary results, CT-0508 was well tolerated after infusion & no dose-limiting toxicities were observed, and showed high CAR expression while immunotherapy was successfully manufactured using macrophages from heavily pretreated, advanced solid tumor patients. Additionally, CT-0508 has received FTD from the US FDA for solid tumors

Ref: PR Newswire | Image: Merck